|

PARP inhibitor + Bevacizumab Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2/3: 1

Top Sponsors

  • N.N. Alexandrov National Cancer Centre1

Indications

  • Primary Peritoneal Cancer1
  • Fallopian Tube Cancers1
  • Ovarian Cancer1
  • Cancer1

Other1 trial

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.